All amounts are in U.S. dollars
QUEBEC CITY, Aug. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and six-month periods ended June 30, 2009.
Second Quarter 2009 Highlights April - Two poster presentations at the American Association of Cancer Research ("AACR") Annual Meeting on in vitro and in vivo results for AEZS-126 in human tumors, and one poster presentation on Phase 1 results with AEZS-112 in solid tumors or lymphoma. - Notification from Nasdaq that the Company had regained compliance with Nasdaq's minimum bid price rules. May - Presentation at the American Society of Clinical Oncology ("ASCO") Annual Meeting of results supporting evaluation of AEZS-108 in prostate cancer. June - Presentation at the ASCO Annual Meeting of positive Phase 2 data on perifosine in advanced metastatic colon cancer and advanced renal cell carcinoma by the Company's partner, Keryx Biopharmaceuticals, Inc. - Acquisition from Ardana Bioscience Ltd. of all assets relating to AEZS-130. - Disclosure of neutral results for the Company's Phase 2 trial in non-small cell lung cancer with perifosine as radioenhancer. - Announcement of the initiation of the extension of the Company's North American Phase 3 efficacy study with cetrorelix in benign prostatic hyperplasia ("BPH"). This extension of the study is sponsored by sanofi-aventis, the Company's partner for the US market. - Poster presentation at the Endocrine Society ("ENDO") Annual Meeting on AEZS-130 as a simple diagnostic test for
|SOURCE AETERNA ZENTARIS INC.|
Copyright©2009 PR Newswire.
All rights reserved